Results 71 to 80 of about 50,558 (217)

Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients

Annals of Hepatology, 2019
Introduction and aim. We assessed the characteristics of virological response to a combination treatment of ombitasvir, paritaprevir, and ritonavir in hepatitis C virus genotype 1-infected elderly Japanese patients.Material and Methods.
Haruki Uojima, Shuzo Kobayashi, Hisashi Hidaka, Takeshi Kinbara, Tomoaki Fujikawa, Tsuyoshi Nakayama, Hiroki Yamanoue, Takayuki Kanemaru, Tohru Hashimotoh, Ji Hyun Sung, Makoto Kako, Wasaburo Koizumi   +11 more
doaj   +1 more source

Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre‐exposure prophylaxis: A focus on polypharmacy and transitions of care in the United States

British Journal of Clinical Pharmacology, EarlyView.
Shawnalyn W. Sunagawa, Elizabeth M. Sherman, Melissa Badowski, David B. Cluck, Spencer H. Durham, Joshua P. Havens, Emily Huesgen, Justin K. Ma, Roxane Rohani, Eric G. Sahloff, Kristy M. Shaeer, Radhika S. Polisetty   +11 more
wiley   +1 more source

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon, Jumpei Kondo, Yuki Tahata, Hayato Hikita, Maki Iwaisako, Muya Matsumoto, Asuka Ogata, Shinji Takamatsu, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Yuichi Yoshida, Masanori Nakahara, Kazuho Imanaka, Mitsuru Sakakibara, Takayuki Yakushijin, Tetsuo Takehara, Takahiro Kodama, Eiji Miyoshi   +19 more
wiley   +1 more source

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model [PDF]

, 2016
Docetaxel (Taxotere(®) ) is currently used intravenously as an anticancer agent and is primarily metabolized by Cytochrome P450 3A (CYP3A). The HIV protease inhibitor ritonavir, a strong CYP3A4 inhibitor, decreased first-pass metabolism of orally ...
Schellens, Jan H M, Song, Ji Ying, Jan H.M. Schellens, Rottenberg, Sven, Beijnen, Jos H., Lagas, Jurjen S, Sven Rottenberg, Lagas, Jurjen S., Hendrikx, Jeroen J M A, Jurjen S. Lagas, Song, Ji-Ying, Pharmacoepidemiology and Clinical Pharmacology, Ji‐Ying Song, Hilde Rosing, Schinkel, Alfred H, Sub Clinical Pharmacology, Jeroen J.M.A. Hendrikx, Rosing, Hilde, Jos H. Beijnen, Beijnen, Jos H, Schinkel, Alfred H., Alfred H. Schinkel   +21 more
core   +3 more sources

HIV viral suppression in children and adolescents who transitioned from ritonavir‐boosted lopinavir‐ to dolutegravir‐based antiretroviral therapy in Lesotho

HIV Medicine, EarlyView.
Abstract Objectives Children and adolescents living with HIV previously taking ritonavir‐boosted lopinavir (LPV/r)‐based antiretroviral therapy (ART) have been programmatically transitioned to dolutegravir (DTG)‐based regimens in many country programs.
Jacob Blankenberger, Teresa L. F. Steffy, Tristan Lee, Thithili Makhesi, Meenakshi Bakaya, Akash Devendra, Pheello Mothepu, Lipontso Motaboli, Nadine Tschumi, Anna Klicpera, Tapiwa Tarumbiswa, Frédérique Chammartin, Lineo K. Thahane, Niklaus D. Labhardt, Jennifer A. Brown   +14 more
wiley   +1 more source

Return of the Ritonavir: A Study on the Stability of Pharmaceuticals Processed in Orbit and Returned to Earth [PDF]

Despite notable progress in realizing the benefits of microgravity, the physical stability of therapeutics processed in space has not been sufficiently investigated.
Haley C., Bauser, Pamela A., Smith, Susan J., Bogdanowich-Knipp, Stephan D., Parent, Jordan M., Croom, Dale K., Purcell, Adrian, Radocea, Ami S., Bhavsar, Larry R., Chan, Daniel T. , Smith, Kenneth H., Condon, Brett A., Cowans, Stephen R., Byrn, Ruba, Alajlouni, Andrew, McCalip   +14 more
core   +2 more sources

Evidence for Time-Dependent Interactions between Ritonavir and Lopinavir/Ritonavir Plasma Levels Following P-Glycoprotein Inhibition in Sprague-Dawley Rats [PDF]

, 2011
The interaction between verapamil, a P-glycoprotein (P-gp) inhibitor, with ritonavir and lopinavir/ritonavir (LPV/r) after acute and chronic treatment was investigated in rats. Rats were divided into 4 groups, viz.
Michelle Viljoen, Michael du Plooy, Malie Rheeders, Viljoen, Michelle, Du Plooy, Michael, Rheeders, Malie   +5 more
core   +1 more source

Antiviral therapy of chronic hepatitis C complicated by systemic cryoglobulinemic vasculitis

Журнал инфектологии, 2016
Literature analysis of published data on mechanisms of infection, disease progression and treatment of chronic hepatitis C, associated with systemic cryoglobulinemic vasculitis and kidney involvement is presented.
N. V. Dunaeva, V. E. Karev, O. A. Vorobyeva, A. V. Mazing, S. V. Lapin, A. V. Smirnov, D. A. Gusev   +6 more
doaj  

Preliminary Comparison of Competitive Efflux and Historical Transwell Assays for Assessing Canine P‐Glycoprotein Substrate Status of Eleven Drugs Representing Ten Different Drug Classes

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Because P‐glycoprotein (P‐gp) influences the disposition of substrate drugs, regulatory agencies recommend ascertaining the P‐gp substrate status of active pharmaceutical ingredients (API's) intended for humans. Transwell‐based assays using P‐gp‐overexpressing human cell lines are routinely used to predict the API's P‐gp substrate status ...
K. L. Mealey, N. S. Burke
wiley   +1 more source

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

BMC Infectious Diseases, 2003
Background Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg BID (APV1200).
Griffith Sandy, Liao Qiming, Richmond Gary J, Pollard Richard B, Gathe Joseph C, Nadler Jeffrey P, Tracey Lancaster C, Hernandez Jaime E, Pappa Keith A   +8 more
doaj   +1 more source